CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A011801 | Alliance | The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb | Adult CIRB - Late Phase Emphasis | Available to Open |
| A092104 | Alliance | A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA9161 | Alliance | A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | Adult CIRB - Late Phase Emphasis | Available to Open |
| A021806 | Alliance | A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| A211901 | Alliance | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions | Cancer Prevention and Control CIRB | Available to Open |
| A211701 | Alliance | A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort | Cancer Prevention and Control CIRB | Completed |
| A091202 | Alliance | A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma | Adult CIRB - Early Phase Emphasis | Available to Open |
| A081801 | Alliance | Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO | Adult CIRB - Late Phase Emphasis | Available to Open |
| A031701 | Alliance | A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations | Adult CIRB - Late Phase Emphasis | Available to Open |
| A221702 | Alliance | ARM: Axillary Reverse Mapping – A Prospective Trial To Study Rates Of Lymphedema And Regional Reccurence After Sentinel Lymph Node Biopsy And Sentinel Lymph Node Biopsy Followed By Axillary Lymph Node Dissection With And Without Axillary Reverse Mapping | Cancer Prevention and Control CIRB | Available to Open |